Project Grant R43TR002441

This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the impact of acid alpha-glucosidase (GAA) deficiency on alveolar repair and autophagy in Pompe disease. The $762,974 award to Duke University aims to evaluate the function of alveolar type 2 (AT2) cells in repairing lung injury, elucidate the effects of GAA deficiency on AT2 cell autophagy and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $986,387 to The Children's Hospital of Philadelphia Research Institute to identify cellular proteins associated with adeno-associated virus (AAV) genomes. The goal is to improve the production and transduction efficiency of recombinant AAV (rAAV) vectors used in gene therapy. The researchers will employ a novel...

This $667,013 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop machine learning models to predict antigen-antibody interactions from high-throughput sequencing data. The key objectives are to: Develop and validate deep learning models to accurately identify antibody-antigen interactions and binding epitopes from massive sequencing data (Aim 1). Integrate B cell...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $284,331 to the University of Massachusetts Medical School (UMass Medical) to conduct research on the stability of gene therapy vectors based on adeno-associated virus (AAV) when challenged by natural viral infections in human hepatocytes. The research aims to develop novel methods to characterize the structure and...

This $195,625 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA Program 93.847 "Diabetes, Digestive, and Kidney Diseases Extramural Research" aims to test whether a single dose of gene therapy using an adeno-associated virus (AAV9) vector delivering the human GALT gene can prevent long-term complications in a rat model of classic galactosemia. The 2-year study will be conducted by Emory University and will assess the...

This federal Project Grant award from the National Institutes of Health's Research Infrastructure Programs (CFDA 93.351) provides $156,136 to Recombinetics Inc. to advance gene therapy for Mucopolysaccharidosis Type IVA (MPS IVA), a rare lysosomal storage disease. The key products and services to be delivered under this award include: 1) Generating a porcine model of MPS IVA to serve as a valuable tool for understanding the disease biology and developing genetic therapies; 2) Conducting a...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This is a Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award of $186,221 will support research to develop personalized sepsis therapies by integrating high-frequency physiological data and electronic health record data to augment sepsis phenotyping and improve predictive algorithms for detecting bloodstream infections. The overarching goal is to enhance the ability to...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...